Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special Access Program assessing SCENESSE® (afamelanotide) in adult patients with erythropoietic protoporphyria (EPP)

Next Previous
X
Search
Trial Profile

Special Access Program assessing SCENESSE® (afamelanotide) in adult patients with erythropoietic protoporphyria (EPP)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Erythropoietic protoporphyria
  • Focus Expanded access; Therapeutic Use

    • Most Recent Events

    • 08 Oct 2024 New trial record
    • 01 Oct 2024 According to CLINUVEL media release, the company has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE (afamelanotide) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP), In 2023 CLINUVEL announced that the first Canadian EPP patient had received treatment with SCENESSE under Canadas Special Access Program (SAP).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top